To prove this hypothesis, instead of A549 cells, we selected H460 human lung cancer cells which also showed sensitivity against Cor‐sugars (Figure 2a), especially, H460 has been well studied to highly overexpress cytotoxic T lymphocyte antigen 4 (CTLA4) and PD‐L1, both as checkpoint proteins play key roles in promoting H460 proliferation and tumor growth.[40, 41] To test the dual‐targeting hypothesis, we selected Atezolizumab as the anti‐PD‐L1 antibody as it has most widely used in the clinic. This evidence concerns the gene CD274 and lung carcinoma.